Randomized Controlled Trial Comparing Low Dose Tadalafil Versus Solifenacin For Management of Overactive Bladder in Women: Multicenter Egyptian National Study

Recruiting now · Phase 4

Conditions studied: Overactive Bladder (OAB), Overactive Bladder Syndrome

In brief

Researchers are studying two medicines to see which works better for women with overactive bladder (OAB). OAB causes sudden urges to urinate, frequent bathroom trips, and sometimes leakage. Women who join the study will be randomly placed into one of two groups: One group will take tadalafil (5 mg), a medicine taken once a day. The other group will take solifenacin (5 mg), a common treatment for OAB, also taken once a day. The study will last 12 weeks. Participants will keep a bladder diary, answer short questionnaires, and have simple urine flow and bladder tests at several visits. The main goal is to find out which medicine lowers OAB symptoms more, such as urgency and frequent urination. Researchers will also look at quality of life, bladder function, and side effects. Women aged 18 to 75 years with OAB symptoms for at least 3 months may be able to take part.

Key facts

Study ID

NCT07416968

Run by

Mansoura University

People needed

480

Starts

2025-09-01

Expected to finish

2026-12-01

Last updated by the study team

2026-02-18

Who can join

Age: 18 and older, up to 75. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• OAB symptoms persisting for ≥3 months
• OAB Symptom Score (OABSS) > 5 and urgency sub-score of OABSS ≥ 2
• Ability and willingness to provide informed consent.

You may not qualify if…

• Active urinary tract infection.
• Stress urinary incontinence (SUI) as primary diagnosis, or mixed urinary incontinence with predominant SUI
• Pelvic organ prolapse stage ≥II according to POP-Q system.
• History of pelvic radiation.
• History of neurosurgical interventions.
• Pregnancy or breastfeeding.
• Neuropathic diseases affecting the lower urinary tract.
• History of genitourinary malignancy.
• Post-void residual urine (PVR) > 150 ml.
• Vesical or lower ureteric stones.
• Uncontrolled diabetes mellitus (HbA1c > 7).
• Any psychological or psychiatric disorders.
• Contraindications or allergy to the used medications.
• History of surgeries in the urinary bladder.
• History of pelvic surgeries within 6 months.
• Voiding dysfunctions.

Where it is running

• Faculty of medicine, Menofia Univeristy — Shibīn al Kawm, Al-Minūfiyyah, Egypt (enrolling)
• Faculty of medicine, Zagazig University — Zagazig, Al-Sharqia, Egypt (enrolling)
• Urology and Nephrology Center, Mansoura University — Al Mansurah, Dakahlia Governorate, Egypt (enrolling)
• Faculty of medicine, Tanta University — Tanta, Gharbia Governorate, Egypt (enrolling)
• faulty of medicine, Tanta Univeristy — Tanta, Gharbia Governorate, Egypt (enrolling)
• Faculty of medicine, minia university — Al Minyā, Egypt (enrolling)
• Faculty of medicine, Alexandria University — Alexandria, Egypt (enrolling)
• Faculty of medicine, Aswan university — Aswān, Egypt (enrolling)
• Faculty of Medicine - Assiut University — Asyut, Egypt (enrolling)
• Faculty of Medicine - Banī Suwayf University — Banī Suwayf, Egypt (enrolling)
• Faculty of medicine, Ain Shams University — Cairo, Egypt (enrolling)
• Cairo University, faculty of medicine — Cairo, Egypt (enrolling)
• Faculty of Medicine, South Valley University — Qina, Egypt (enrolling)
• Faculty of medicine, Sohag Univeristy — Sohag, Egypt (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.